Where can I find the specific financial results for Edwards Lifesciences for the third quarter of 2021?

The specific financial results for the third quarter of 2021 are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. You will need to access Exhibit 99.1 for the complete financial figures and commentary.

What are the key financial metrics that will be included in the press release?

While this 8-K does not contain the specific metrics, the press release (Exhibit 99.1) typically includes details on revenue, earnings per share (EPS), sales performance by product segment (e.g., TAVR, Surgical Heart Valve Therapy, Critical Care, Advanced Monitoring), and potentially forward-looking guidance.

Is there any new guidance or outlook provided in this filing?

This 8-K filing itself does not provide new guidance. Any updated financial outlook or guidance for future periods would be found within the press release (Exhibit 99.1) that is incorporated by reference.

What is the significance of the information being 'furnished' rather than 'filed'?

When information is 'furnished' under Item 2.02 of an 8-K, it is generally for disclosure purposes and is not subject to the same liability provisions under Section 18 of the Securities Exchange Act of 1934 as information that is 'filed'. Investors should still consider this information important for their investment decisions.

EW 8-K: Earnings & Results

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on October 27, 2021, to report its financial results for the third quarter of 2021. The key event detailed in this filing is the issuance of a press release (Exhibit 99.1) containing the company's performance for the quarter ending in September 2021. While the 8-K itself is brief and primarily serves to incorporate the press release by reference, investors should refer to Exhibit 99.1 for detailed financial figures, operational updates, and management commentary. This filing is crucial for investors tracking EW's performance against expectations and its progress in its core markets, particularly in transcatheter aortic valve replacement (TAVR) and critical care. The information provided in the accompanying press release will shed light on sales growth, profitability, and any forward-looking statements or guidance the company may have issued, enabling investors to assess the company's current financial health and future prospects.

Key Highlights

1Edwards Lifesciences filed an 8-K on October 27, 2021, to report Q3 2021 financial results.
2The primary content of the filing is a press release (Exhibit 99.1) detailing the company's financial performance.
3Investors should review the furnished press release for specific Q3 2021 financial data and operational updates.
4The filing incorporates the press release by reference, making it the essential source of information for the quarter's results.
5The 8-K indicates the financial results covered are for the third quarter of 2021.
6The information furnished under Item 2.02 is not considered 'filed' for the purposes of Section 18 of the Exchange Act.

Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 27, 2021)

Summary

Key Highlights

Frequently Asked Questions